Adam Stone's most recent trade in Solid Biosciences Inc was a trade of 77,500 Director Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Solid Biosciences Inc | Adam Stone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 77,500 | 77,500 | - | - | Director Stock Option (Right to Buy) | |
| Arya Sciences Acquisition ... | Adam Stone | Director, Chief Executive Officer, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Jul 2024 | 2,647,500 | 0 | - | - | Class B ordinary shares | |
| Arya Sciences Acquisition ... | Adam Stone | Director, Chief Executive Officer, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Jul 2024 | 1,000,000 | 2,647,500 | - | - | Class B ordinary shares | |
| Arya Sciences Acquisition ... | Adam Stone | Director, Chief Executive Officer, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Jul 2024 | 499,000 | 0 | - | - | Class A ordinary shares | |
| Perceptive Capital Solutio... | Adam Stone | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 10.00 per share. | 13 Jun 2024 | 286,250 | 286,250 | - | 10 | 2,862,500 | Class A ordinary shares |
| Solid Biosciences Inc | Adam Stone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 34,400 | 34,400 | - | - | Director Stock Option (Right to Buy) | |
| LianBio - ADR | Adam Stone | Director, Interim CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.52 per share. | 15 Feb 2024 | 36,300 | 36,300 | - | 2.5 | 91,476 | Ordinary Shares |
| LianBio - ADR | Adam Stone | Director, Interim CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 36,300 | 0 | - | - | Stock Option (Right to Buy) | |
| LianBio - ADR | Adam Stone | Director, Interim CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. | 15 Feb 2024 | 19,218 | 17,082 | - | 4.8 | 91,478 | Ordinary Shares |
| Solid Biosciences Inc | Adam Stone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 9,650 | 9,650 | - | - | Director Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Adam Stone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2022 | 9,650 | 9,650 | - | - | Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Adam Stone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 51,000 | 51,000 | - | - | Stock Option (Right to Buy) | |
| Arya Sciences Acquisition ... | Adam Stone | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 10.00 per share. | 02 Mar 2021 | 499,000 | 499,000 | - | 10 | 4,990,000 | Class A ordinary shares |